A method for deconvoluting measured mass spectrometry data, the method comprising: receiving measured mass spectrometry data representing at least two molecular moieties each having a respective isotopic pattern, wherein at least two of said isotopic patterns overlap; iteratively filling a set of mass channels to produce an approximated version of the mass spectrometry data, said iterative filling comprising a number of iterations, each iteration comprising filling one or more of the mass channels with a chunk of intensity data according to the isotopic pattern of a respective one of the two or more molecular moieties selected for said iteration; terminating said iterative filling when a fitness criterion is met indicating a fit of the approximated version of the mass spectrometry data to the measured mass spectrometry data; and determining the amount of each molecular moiety that produced the measured mass spectrometry data based on the total amount of fills according to the respective isotopic pattern of said molecular moiety.

The present invention provides novel peptides (e.g., peptides, macrocyclic peptides, mini-proteins) that modulate protein-protein interactions or salts thereof, and methods of making and using the inventive peptides. In some embodiments, the peptides are high affinity inhibitors (e.g., K.sub.D of at most 100 nM, at most 10 nM, at most 1 nM) of a protein-protein interaction. In certain embodiments, these peptides interfere with p53-MDM2 binding interactions (e.g., by binding to MDM2 (GenBank® Gene ID: 4193)). In some embodiments, the peptides interfere with the dimerization of the C-terminal domain of the human immunodeficiency virus (HIV) capsid protein (C-CA), comprising residues 146-231 of the HIV capsid protein (e.g., by binding to the C-terminal domain of the HIV capsid protein (C-CA), thereby inhibiting the dimeric interface of HIV capsid protein, thereby inhibiting viral assembly). These inventive peptides were rapidly generated and identified using novel methods described herein comprising combinatorial peptide synthesis and/or solution affinity selection.

This application relates to molecular biology, and more specifically to a method which uses the molecular recognition between a target molecule ligand and an aptamer, magnetic separation and MS qualitative and quantitative analysis to enable the association between the detection of multi molecules and information of multiple functional groups, and effectively determine the correlation between molecules and functional groups of the body or tissue. This application can easily purify the target molecules by magnetic separation and can effectively obtain the target molecule group based on the high specificity and affinity of the aptamer. In addition, based on the MS detection, this application can effectively perform the qualification and quantification of the multi molecules, achieving the secondary molecular detection and improving the detection accuracy. The simultaneous qualification and quantification of multi molecules can not only accurately reflect the relationship among molecules, but also reveal the interrelationship among body functions, playing a significant role in the proteomics and genomics research and clinical molecular detection.

A mass isolation device selects a precursor ion of a sample that has been digested using a protease. A first fragmentation device fragments the precursor ion using collision-induced dissociation (CID), and the resulting product ions are analyzed using a mass analyzer producing a CID spectrum. A list of theoretical candidate glycopeptide sequences is determined from CID spectrum. The mass isolation device again selects the precursor ion of the sample. A second fragmentation device fragments the precursor ion using electron-based dissociation (ExD), and the resulting product ions are analyzed using the mass analyzer producing a CID spectrum. For each sequence of the list, the sequence is computationally fragmented, producing theoretical fragments, mass-to-charge ratio (m/z) values are calculated for the theoretical fragments, and the sequence is scored using c and z fragment matching rules. The highest scoring sequence is identified as a peptide sequence of a glycopeptide of the sample.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.

A method of measuring and identifying metabolites of a tryptamine compound, by obtaining a sample from an individual, and measuring and identifying metabolites of the tryptamine compound in the sample by performing a LC-MS/MS analysis. A method of adjusting dosing in patients with tryptamine compound-assisted psychotherapy in therapeutic drug monitoring (TDM), by obtaining a sample from an individual, measuring and identifying metabolites of the tryptamine compounds in the sample by performing a LC-MS/MS analysis, and adjusting a dose of the tryptamine compounds based on the measured metabolites.

Disclosed are methods, systems, and computer program products for using liquid chromatography/tandem mass spectrometry (LC-MS/MS) for the analysis of endogenous biomarkers, such as PGD.sub.2, in a biological sample. More specifically, the methods, systems, and computer program products are described for detecting and quantifying the amount of an PGD.sub.2 in a sample. The quantitative analysis may be helpful in making clinical diagnoses.

Methods for identifying a binding site between a protein pharmaceutical product and a host-cell protein (HCP) using hydrogen exchange mass spectrometry are provided. The present application also provides methods to modify protein pharmaceutical products to eliminate the cleavage or modification by HCPs. In addition, the present application provides methods to block the identified binding site in protein pharmaceutical products to eliminate the cleavage or modification by HCPs.

Methods and uses of compositions (e.g. comprising one or more microbial strains) are disclosed.